{"id":516456,"date":"2021-07-22T09:02:04","date_gmt":"2021-07-22T13:02:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/"},"modified":"2021-07-22T09:02:04","modified_gmt":"2021-07-22T13:02:04","slug":"moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/","title":{"rendered":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023"},"content":{"rendered":"

<\/p>\n

Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Moderna, Inc.<\/a> (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with Taiwan for 20 million doses of Moderna\u2019s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023. This new supply agreement is in addition to the prior agreement for 5 million doses in 2021.\n<\/p>\n

\n\u201cWe thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine and our updated variant booster candidate, if approved,\u201d said St\u00e9phane Bancel, Moderna\u2019s Chief Executive Officer. \u201cWe remain committed to making our vaccine available around the world.\u201d\n<\/p>\n

About Moderna<\/b><\/p>\n

\nIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna\u2019s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.\n<\/p>\n

\nModerna\u2019s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science<\/i> for the past six years. To learn more, visit www.modernatx.com<\/a>.\n<\/p>\n

Forward Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company\u2019s development of a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also referred to as the Moderna COVID-19 Vaccine), as well as booster vaccine candidates; the Company\u2019s agreement to supply the vaccine to Taiwan, and the anticipated number of doses and timing for delivery of vaccine supply. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading \u201cRisk Factors\u201d in Moderna\u2019s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna\u2019s current expectations and speak only as of the date hereof.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210722005629\/en\/<\/a><\/span><\/p>\n

Media:
\n<\/b>
Colleen Hussey
\n
Director, Corporate Communications
\n
617-335-1374
\n
Colleen.Hussey@modernatx.com<\/a><\/p>\n

Investors:
\n<\/b>
Lavina Talukdar
\n
Senior Vice President & Head of Investor Relations
\n
617-209-5834
\n
Lavina.Talukdar@modernatx.com<\/a><\/p>\n

KEYWORDS:<\/b> United States Taiwan North America Asia Pacific Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Other Health Health Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with Taiwan for 20 million doses of Moderna\u2019s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023. This new supply agreement is in addition to the prior agreement for 5 million doses in 2021. \u201cWe thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine … <\/p>\n

Continue reading “Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516456","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nModerna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with Taiwan for 20 million doses of Moderna\u2019s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023. This new supply agreement is in addition to the prior agreement for 5 million doses in 2021. \u201cWe thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine … Continue reading "Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T13:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023\",\"datePublished\":\"2021-07-22T13:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/\"},\"wordCount\":675,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/\",\"name\":\"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-22T13:02:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/","og_locale":"en_US","og_type":"article","og_title":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk","og_description":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with Taiwan for 20 million doses of Moderna\u2019s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023. This new supply agreement is in addition to the prior agreement for 5 million doses in 2021. \u201cWe thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine … Continue reading \"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T13:02:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023","datePublished":"2021-07-22T13:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/"},"wordCount":675,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/","name":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-22T13:02:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210722005629r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-new-supply-agreement-with-taiwan-for-20-million-doses-of-modernas-covid-19-vaccine-and-variant-booster-vaccine-candidate-in-2022-and-15-million-doses-in-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna\u2019s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516456"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516456\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}